eligibility_summary
Include: ≥14y R/R B‑ALL (not EM‑only) incl chemo‑refractory, CR≤12m, salvage‑failure, or post‑HSCT relapse/MRD+, CD19+, BM blasts ≥5%, ECOG 0–2, LVEF≥50%, adequate renal/hepatic, life>3m, neg pregnancy test & contraception 1y, consent. Exclude: pregnancy/lactation, uncontrolled CNSL/epilepsy, immunodeficiency/autoimmune on IS, recent immune‑cell tx/DLI, anti‑FMC63/DSA+, uncontrolled infection or serious cardiac/effusions, stroke/ICH<3m, major surgery/trauma<28d, investigator discretion.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06056752 evaluates QH103 Cell Injection: an allogeneic CD19-directed CAR‑γδ T‑cell therapy (biological). These engineered γδ T cells express a CAR to bind CD19 on B cells and mediate MHC‑independent cytotoxic killing, aiming to clear relapsed/refractory B‑ALL with potentially lower GVHD risk. Conditioning uses fludarabine (drug, purine analog antimetabolite) and cyclophosphamide (drug, alkylating agent) for lymphodepletion to enhance CAR‑T expansion. Targets/pathways: CD19 on malignant B cells, T‑cell activation and cytotoxic effector pathways (e.g., perforin/granzyme), γδ T‑cell innate-like tumor recognition.